NCT07160634View on ClinicalTrials.gov

A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

January 31, 2029

Study Completion Date

January 31, 2034

Conditions
Duchenne Muscular Dystrophy
Interventions
DRUG

SGT-003

Adeno-associated virus (AAV)-based gene therapy that delivers a codon-optimized and CpG island-minimized human 5-repeat microdystrophin (h-μD5)

DRUG

Placebo

IV infusion

All Listed Sponsors
lead

Solid Biosciences Inc.

INDUSTRY

NCT07160634 - A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE) | Biotech Hunter | Biotech Hunter